{"nctId":"NCT02134353","briefTitle":"A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects","startDateStruct":{"date":"2014-09","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":423,"armGroups":[{"label":"Experimental arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Inhaled mannitol"]},{"label":"Arm B - Control","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Comparator: Arm B - Control"]}],"interventions":[{"name":"Inhaled mannitol","otherNames":[]},{"name":"Placebo Comparator: Arm B - Control","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Have given written informed consent to participate in this trial in accordance with local regulations;\n2. Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value â‰¥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype);\n3. Be aged at least 18 years old;\n4. Have FEV1 \\> 40 % and \\< 90% predicted (using NHanes III \\[1\\]);\n5. Be able to perform all the techniques necessary to measure lung function;\n6. Be adherent with maintenance therapies (antibiotics and or rhDNase), if used, for at least 80% of the time in the two weeks prior to visit 1 and\n7. If rhDNase and/or maintenance antibiotic are being used treatment must have been established at least 1 month prior to screening (Visit 0). The subject should remain on the rhDNase and / or maintenance antibiotics for the duration of the trial. The subject should not commence treatment with rhDNase or maintenance antibiotics during the trial\n\nExclusion Criteria:\n\n1. Be investigators, site personnel directly affiliated with this trial, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted;\n2. Be considered \"terminally ill\" or eligible for lung transplantation;\n3. Have had a lung transplant;\n4. Be using maintenance nebulized hypertonic saline in the 2 weeks prior to visit 1;\n5. Have had a significant episode of hemoptysis (\\> 60 mL) in the three months prior to Visit 0;\n6. Have had a myocardial infarction in the three months prior to Visit 0;\n7. Have had a cerebral vascular accident in the three months prior to Visit 0;\n8. Have had major ocular surgery in the three months prior to Visit 0;\n9. Have had major abdominal, chest or brain surgery in the three months prior to Visit 0;\n10. Have a known cerebral, aortic or abdominal aneurysm;\n11. Be breast feeding or pregnant, or plan to become pregnant while in the trial;\n12. Be using an unreliable form of contraception (female subjects at risk of pregnancy only);\n13. Be participating in another investigative drug trial, parallel to, or within 4 weeks of screening (Visit 0);\n14. Have a known allergy to mannitol;\n15. Be using non-selective oral beta blockers;\n16. Have uncontrolled hypertension -i.e. systolic BP \\> 190 and / or diastolic BP \\> 100;\n17. Have a condition or be in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the subject's participation in the trial;or\n18. Have a failed or incomplete MTT at trial entry (as evaluated in Section 8.1.1.1).\n19. The subject must not commence treatment with rhDNase or maintenance antibiotics during the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in FEV1 (mL) From Baseline (Visit 1) Over the 26-week Treatment Period (to Visit 4).","description":"The mean absolute change from baseline FEV1 (mL) over 26 weeks (measured at week 6, 14 and 26) will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach.\n\nLeast square means presented are for the average change over the 6, 14, and 26 week visits.\n\nMissing values due to withdrawal for reasons related to safety or efficacy were imputed using a baseline observation carried forward approach (BOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline FVC (mL) Over the 26-week Treatment Period","description":"To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control for improving lung function as measured by mean change from baseline forced vital capacity (FVC) (mL) over the 26-week treatment period in adult subjects with cystic fibrosis (CF).\n\nThe mean absolute change from baseline FVC (mL) over 26 weeks will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach.\n\nLeast square means presented are for the change from baseline averaged over the treatment period (ie the average of the changes at 6 weeks, 14 weeks and 26 weeks).\n\nMissing values due to withdrawal for reasons related to safety or efficacy were imputed using a baseline observation carried forward approach (BOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"-12","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to First Pulmonary Exacerbation Over the 26-week Treatment Period","description":"To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control in increasing the time to first protocol defined pulmonary exacerbation over the 26-week treatment period in adult subjects with CF.\n\nProtocol defined pulmonary exacerbations are those where 4 or more symptoms are recorded and are treated with IV antibiotics","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Days on Antibiotics (Oral, Inhaled or IV) Due to Pulmonary Exacerbation","description":"To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is superior to control for decreasing the number of days on antibiotics due to protocol defined pulmonary exacerbations.\n\nOverlapping antibiotics are counted separately.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"31.25"},{"groupId":"OG001","value":"5.5","spread":"17.94"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Days in Hospital Due to Pulmonary Exacerbation","description":"To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is superior to control for decreasing the number of days in hospital due to protocol defined pulmonary exacerbation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"199","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Rate of Pulmonary Exacerbations Over the 26-week Treatment Period","description":"To determine whether inhaled mannitol (400 mg b.i.d.) decreases the rate of protocol defined pulmonary exacerbations over the 26-week treatment period compared to control in adult subjects with CF.\n\nProtocol defined pulmonary exacerbations defined by having 4 or more symptoms and treated with IV antibiotics.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"185","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Incidence of Pulmonary Exacerbations","description":"To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is superior to control for decreasing incidence of protocol defined pulmonary exacerbations, where incidence is defined as the proportion of subjects with 1 or more exacerbation during the 26 week period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change From Baseline in Ease of Expectoration Measured Using a Visual Analogue Scale (VAS) Over 26 Weeks","description":"To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is superior to control for improving ease of expectoration.\n\nThe visual analogue scale (VAS) was 10cm. The position marked by the subject was converted into a score from 0 to 100 where 0 was the worst possible outcome and 100 was the best possible outcome.\n\nThe VAS was completed at baseline, 6, 14 and 26 weeks. The mean absolute change from baseline over 26 weeks (ie the average of the changes at 6,14 and 26 weeks) is the outcome measure and will be compared between the two treatment groups with a REML based repeated measures approach.\n\nLeast square means presented are for the change from baseline averaged over the treatment period (ie the average of the changes at 6 weeks, 14 weeks and 26 weeks).\n\nMissing values due to withdrawal for reasons related to safety or efficacy were imputed using a baseline observation carried forward approach (BOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.795","spread":null},{"groupId":"OG001","value":"0.537","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Over 26 Weeks in CFQ-R Respiratory Domain Score","description":"To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is superior to control for improving respiratory symptoms measured by Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain.\n\nThe CFQ-R respiratory domain score is a scale from 0 to 100. Higher scores are a more favourable response.\n\nThe mean absolute change from baseline over 26 weeks (measured at week 6, 14 and 26) will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach.\n\nLeast square means presented are for the change from baseline averaged over the treatment period (ie the average of the changes at 6 weeks, 14 weeks and 26 weeks).\n\nMissing values due to withdrawal for reasons related to safety or efficacy were imputed using a baseline observation carried forward approach (BOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.308","spread":null},{"groupId":"OG001","value":"-0.562","spread":null}]}]}]},{"type":"POST_HOC","title":"Absolute Change in Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25-75) Over the 26-week Treatment Period.","description":"The mean absolute change from baseline FEF25-75 (mL/s) over weeks 6, 14 and 26 will be compared between the two treatment groups with a REML based repeated measures approach\n\nLeast square means presented are for the change from baseline averaged over the treatment period (ie the average of the changes at 6 weeks, 14 weeks and 26 weeks).\n\nMissing values due to withdrawal for reasons related to safety or efficacy were imputed using a baseline observation carried forward approach (BOCF).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":207},"commonTop":["Condition Aggravated","Cough","Haemoptysis","Headache","Upper Respiratory Tract Infection"]}}}